These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6961115)

  • 1. Cytogenetic changes during tumor progression towards invasion, metastasis and immune escape in the Eb/ESb model system.
    Dzarlieva R; Schirrmacher V; Fusenig NF
    Int J Cancer; 1982 Nov; 30(5):633-42. PubMed ID: 6961115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic variation in cancer metastasis: immune escape versus immune control.
    Schirrmacher V; Fogel M; Russmann E; Bosslet K; Altevogt P; Beck L
    Cancer Metastasis Rev; 1982; 1(3):241-74. PubMed ID: 6985248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suggestive evidence that the highly metastatic variant ESb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage.
    Larizza L; Schirrmacher V; Graf L; Pflüger E; Peres-Martinez M; Stöhr M
    Int J Cancer; 1984 Nov; 34(5):699-707. PubMed ID: 6500746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic and genotypic differences between high- and low-metastatic related tumor lines and the problem of tumor progression and variant generation.
    Schirrmacher V; Dzarlieva R; Altevogt P; Fogel M; Waller CA; Dennis JW; Springer GF; Vlodavsky I; Kramer M; Cheingsong-Popov R
    Symp Fundam Cancer Res; 1983; 36():81-99. PubMed ID: 6332358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different expression of Lyt differentiation antigens and cell surface glycoproteins by a murine T lymphoma line and its highly metastatic variant.
    Altevogt P; Kurnick JT; Kimura AK; Bosslet K; Schirrmacher V
    Eur J Immunol; 1982 Apr; 12(4):300-7. PubMed ID: 6124426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. X. Immunoselection of tumor variants differing in tumor antigen expression and metastatic capacity.
    Schirrmacher V; Bosslet K
    Int J Cancer; 1980 Jun; 25(6):781-8. PubMed ID: 14768708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different patterns of lectin binding and cell surface sialylation detected on related high- and low-metastatic tumor lines.
    Altevogt P; Fogel M; Cheingsong-Popov R; Dennis J; Robinson P; Schirrmacher V
    Cancer Res; 1983 Nov; 43(11):5138-44. PubMed ID: 6616451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Ia antigens in a murine T-lymphoma variant.
    Graf L; Koch N; Schirrmacher V
    Mol Immunol; 1985 Dec; 22(12):1371-7. PubMed ID: 3938525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoconjugates of murine tumor lines with different metastatic capacities. I. Differences in fucose utilization and in glycoprotein patterns.
    Schwartz R; Schirrmacher V; Mühlradt PF
    Int J Cancer; 1984 Apr; 33(4):503-9. PubMed ID: 6706434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and enhanced secretion of proteochondroitin sulphate in a metastatic variant of a mouse lymphoma cell line.
    Schwartz-Albiez R; Steffen I; Lison A; Güttler N; Schirrmacher V; Keller R
    Br J Cancer; 1988 Jun; 57(6):569-75. PubMed ID: 3408644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone marrow-derived macrophage.
    Larizza L; Schirrmacher V; Pflüger E
    J Exp Med; 1984 Nov; 160(5):1579-84. PubMed ID: 6491605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes.
    Schirrmacher V; Bosslet K; Shantz G; Clauer K; Hübsch D
    Int J Cancer; 1979 Feb; 23(2):245-52. PubMed ID: 83969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to interleukin (IL)-2 and to combination cytokine therapy with IL-2/IL-1 beta and IL-1 beta/interferon-alpha/beta.
    Gabriele L; Proietti E; Greco G; Venditti M; Gresser I; Schirrmacher V; Von Hoegen P; Testa U; Modesti A; Cianfriglia M
    Invasion Metastasis; 1993; 13(3):147-62. PubMed ID: 8112975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoma cell interaction with cultured vascular endothelial cells and with the subendothelial basal lamina: attachment, invasion and morphological appearance.
    Vlodavsky I; Schirrmacher V; Ariav Y; Fuks Z
    Invasion Metastasis; 1983; 3(2):81-97. PubMed ID: 6677623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualitative differences in position of sialylation and surface expression of glycolipids between murine lymphomas with low metastatic (Eb) and high metastatic (ESb) potentials and isolation of a novel disialoganglioside (GD1 alpha) from Eb cells.
    Murayama K; Levery SB; Schirrmacher V; Hakomori S
    Cancer Res; 1986 Mar; 46(3):1395-402. PubMed ID: 3484680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of cellular and extracellular plasma membrane vesicles from a low metastatic lymphoma (Eb) and its high metastatic variant (ESb): inhibitory capacity in cell-cell interaction systems.
    Schirrmacher V; Barz D
    Biochim Biophys Acta; 1986 Aug; 860(2):236-42. PubMed ID: 3488762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis.
    Vlodavsky I; Fuks Z; Bar-Ner M; Ariav Y; Schirrmacher V
    Cancer Res; 1983 Jun; 43(6):2704-11. PubMed ID: 6601984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb).
    Bosslet K; Schirrmacher V
    Int J Cancer; 1982 Feb; 29(2):195-202. PubMed ID: 6977502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoconjugates of murine tumor lines with different metastatic capacities. II. Diversity of glycolipid composition.
    Schwartz R; Kniep B; Müthing J; Mühlradt PF
    Int J Cancer; 1985 Nov; 36(5):601-7. PubMed ID: 4055130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific eradication of micrometastases by transfer of tumour-immune T cells from major-histocompatibility-complex congenic mice.
    Schirrmacher V; von Hoegen P; Griesbach A; Schild HJ; Zangemeister-Wittke U
    Cancer Immunol Immunother; 1991; 32(6):373-81. PubMed ID: 1826094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.